Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte (Nasdaq: PCVX) will report Q4 and full-year 2025 financial results and provide a business update on February 24, 2026 after market close.
Rhea-AI Summary
Vaxcyte (Nasdaq: PCVX) will report Q4 and full-year 2025 financial results and provide a business update on February 24, 2026 after market close. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT.
A live webcast will be available on the company website and a replay will be accessible for about 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PCVX
In the Feb 11 session, PCVX gained 0.67%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings date
- February 24, 2026
- Scheduled Q4 and full-year 2025 results release
- Conference time ET
- 4:30 p.m. ET
- Start time of earnings conference call
- Conference time PT
- 1:30 p.m. PT
- Start time of earnings conference call
- Domestic dial-in
- 800-445-7795
- U.S. conference call access number
- International dial-in
- 785-424-1699
- International conference call access number
- Conference ID
- PCVX4Q25
- Identifier for the Q4 2025 earnings call
- Webcast replay window
- 30 days
- Approximate availability of earnings call replay
Historical Context
-
Guggenheim biotech summit fireside chat with webcast access for investors.
-
Closing of $632.5M underwritten public offering including full underwriter option.
-
Pricing of $550M public offering of common stock at $50 per share.
-
Commencement of proposed $500M common stock and pre-funded warrants offering.
-
Advancement of VAX-31 adult Phase 3 and infant Phase 2 vaccine programs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT.
To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), conference ID PCVX4Q25. A live webcast of the conference call will be available in the Investors & Media section of the Company’s website at www.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference call.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.